Dr. Edginton is an Associate Professor and Program Assessment Officer at the School of Pharmacy at the University of Waterloo in Ontario, Canada. She is also the Chair of the University’s Clinical Research Ethics Board and is co-owner of a PBPK consulting company called Design2Code Inc. Before coming to the University, she worked in the Systems Biology group at Bayer Technology Services in Leverkusen, Germany. As an academic, Dr. Edginton’s research focuses on the development and application of physiologically-based pharmacokinetic (PBPK) models and simulation techniques in both the areas of pharmaceuticals and human health risk assessment. Her research examines how the physiology of sub-populations such as children and patients with disease (e.g.liver cirrhosis) affect the pharmacokinetics of drugs and how this information can be integrated into PBPK models for the optimization of drug therapy. Of special interest is the physiological scaling of PBPK models from adults to children as a means to predict drug pharmacokinetics and quantify appropriate dosing regimens for clinical trials in children.